DK1675846T3 - Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon - Google Patents

Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon

Info

Publication number
DK1675846T3
DK1675846T3 DK04793893.1T DK04793893T DK1675846T3 DK 1675846 T3 DK1675846 T3 DK 1675846T3 DK 04793893 T DK04793893 T DK 04793893T DK 1675846 T3 DK1675846 T3 DK 1675846T3
Authority
DK
Denmark
Prior art keywords
pyridin
trifluoromethylbenzyl
methanone
triazol
chlorophenyl
Prior art date
Application number
DK04793893.1T
Other languages
Danish (da)
English (en)
Inventor
Pamela Kaye Footman
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Shella Lenyonga Tameze
Carsten Weber
Carsten Timpe
David Scott Coffey
Alfio Borghese
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1675846T3 publication Critical patent/DK1675846T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04793893.1T 2003-10-24 2004-10-12 Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon DK1675846T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (1)

Publication Number Publication Date
DK1675846T3 true DK1675846T3 (da) 2010-05-31

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04793893.1T DK1675846T3 (da) 2003-10-24 2004-10-12 Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon

Country Status (28)

Country Link
US (1) US7381826B2 (enExample)
JP (1) JP4959336B2 (enExample)
KR (1) KR100848407B1 (enExample)
CN (1) CN1863791B (enExample)
AR (1) AR046131A1 (enExample)
AT (1) ATE462700T1 (enExample)
AU (1) AU2004285855B8 (enExample)
BR (1) BRPI0415010B8 (enExample)
CA (1) CA2542140C (enExample)
CL (2) CL2009001311A1 (enExample)
CR (1) CR8353A (enExample)
DE (1) DE602004026333D1 (enExample)
DK (1) DK1675846T3 (enExample)
EA (1) EA008881B1 (enExample)
EC (1) ECSP066517A (enExample)
ES (1) ES2340772T3 (enExample)
HR (1) HRP20100207T1 (enExample)
IL (1) IL174926A0 (enExample)
MA (1) MA28329A1 (enExample)
MY (1) MY157375A (enExample)
NO (1) NO335090B1 (enExample)
NZ (2) NZ545917A (enExample)
PE (1) PE20050481A1 (enExample)
PT (1) PT1675846E (enExample)
TW (1) TW200524906A (enExample)
UA (1) UA82901C2 (enExample)
WO (1) WO2005042515A1 (enExample)
ZA (1) ZA200603234B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2121610T1 (sl) 2006-12-20 2014-08-29 Eli Lilly & Company Nove vmesne spojine in postopek, ki je uporaben pri pripravi (2-(1-(3,5-bistrifluorometil-benzil)-5-piridin-4-il-1h-(1,2,3)triazol- 4-il)-piridin-3-il)-(2-klorofenil)-metanona
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
PT3265087T (pt) 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
US11549147B2 (en) 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
CA3101210A1 (en) 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
MX2020008456A (es) * 2018-09-28 2020-09-25 Vanda Pharmaceuticals Inc Uso de tradipitant para tratar la cinetosis.
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
EP4110335B1 (en) 2020-02-25 2025-10-15 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
HK1045507A1 (zh) * 1999-08-12 2002-11-29 Vertex Pharmaceuticals Incorporated C-jun n-末端激酶(jnk)及其他蛋白质激酶的抑制物
JP2003513095A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド タキキニン受容体アンタゴニストの多形
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
DK1501809T3 (da) * 2002-04-26 2008-05-13 Lilly Co Eli Trizolderivater som tachykininreceptorantagonister

Also Published As

Publication number Publication date
NO20062371L (no) 2006-05-24
NZ580480A (en) 2010-02-26
AU2004285855B8 (en) 2011-04-28
NZ545917A (en) 2009-11-27
IL174926A0 (en) 2006-08-20
PT1675846E (pt) 2010-04-20
UA82901C2 (en) 2008-05-26
EA008881B1 (ru) 2007-08-31
MA28329A1 (fr) 2006-12-01
TW200524906A (en) 2005-08-01
US20070078166A1 (en) 2007-04-05
EA200600829A1 (ru) 2006-08-25
PE20050481A1 (es) 2005-09-20
KR100848407B1 (ko) 2008-07-28
JP2007509143A (ja) 2007-04-12
CA2542140C (en) 2012-05-29
JP4959336B2 (ja) 2012-06-20
ES2340772T3 (es) 2010-06-09
ATE462700T1 (de) 2010-04-15
CN1863791B (zh) 2011-12-07
CL2009001311A1 (es) 2009-10-02
CR8353A (es) 2006-06-06
AR046131A1 (es) 2005-11-23
CA2542140A1 (en) 2005-05-12
AU2004285855A1 (en) 2005-05-12
WO2005042515A1 (en) 2005-05-12
MY157375A (en) 2016-06-15
ECSP066517A (es) 2006-10-10
CN1863791A (zh) 2006-11-15
CL2009001310A1 (es) 2009-12-04
US7381826B2 (en) 2008-06-03
DE602004026333D1 (de) 2010-05-12
ZA200603234B (en) 2007-07-25
AU2004285855B2 (en) 2010-12-23
NO335090B1 (no) 2014-09-08
BRPI0415010A (pt) 2006-11-07
BRPI0415010B1 (pt) 2019-07-09
HRP20100207T1 (hr) 2010-05-31
KR20060061388A (ko) 2006-06-07
BRPI0415010A8 (pt) 2018-05-08
BRPI0415010B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PT1675846E (pt) Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
IS8307A (is) Fenýl eða pýridýl amíð efnasambönd sem prostaglandín E2 mótlyf
IS8280A (is) 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2
ATE404537T1 (de) Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
IS7599A (is) Heterósýklískir kínasatálmar
DE60125980D1 (de) P38kinase-inhibitoren vom piperidin/piperazin-typ
NO20034308D0 (no) Nye tyrokinase-inhibitorer
DE60128709D1 (de) Triazol-verbindungen als protein-kinase-inhibitoren
IS8340A (is) Fjölbreyttar myndir 3-(4-amínó-1-oxó-1,3 díhýdró-ísóindol-2-ýl)-piperidín-2,6-díons
PL2317687T3 (pl) Kontrola dostępu do szybkiego medium
ATE428701T1 (de) Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-
DE50313207D1 (de) Zugangskontrolle bei paketorientierten netzen
NO20052474D0 (no) Amort form av esomeprazolsalter
EE200300070A (et) Asendatud imidasoolid kui TAFIa inhibiitorid
DK2121610T3 (da) Hidtil ukendt mellemprodukt og fremgangsmåde, som er anvendelige ved fremstilling af {2-[1-(3,5-bis-trifluormethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorphenyl)-methanon
ATE292128T1 (de) Piperidinderivate als neurokinin 1 antagonisten
DK1505066T3 (da) Polymorf af 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-IL]-1-piperidinyl]ethyl]-alfa,alfa-dimethylbenzeneddikesyre
NO20032315L (no) 4-(bifenylkarbonylamino)piperidinderivater som MTP- inhibitorer
DE602004012724D1 (de) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridinderivaten zur verwendung als serotonin-wiederaufnahmehemmer
ATE380549T1 (de) Substituierte 1-phenethylpiperidinverbindungen, die unter anderem als analgetika verwendung finden
PL1675846T3 (pl) Nowe krystaliczne postacie {2-[1-(3,5-bis-trifluoro-metylobenzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)metanonu
DE50308983D1 (de) Zugangskontrolle bei paketorientierten netzen
ITTO20030323A1 (it) Gruppo per l'immagazzinamento di spezzoni di lastre
HK1092475A (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
IS8093A (is) Kristölluð N-formýlhýdroxýlamínefnasambönd